

CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukaemia – a case report

Ruth-Maria Urbantat¹, Valentin Popper¹, Elisabeth Menschel¹, Michael Pfeilstoecker¹, Ernst Forjan¹, Alexander Nader¹, Caroline Sieghart¹, Felix Keil¹, and Elisabeth Koller¹

¹Hanusch Hospital

July 30, 2020

Abstract

CPX-351 is a promising new therapeutic option for patients with treatment related (tAML) or secondary acute myeloid leukemia (sAML). It exceeded classic 7+3 therapy in overall survival (OS) and complete remission rates (CR) while providing a similar risk profile. Until now, this sub-group of AML patients had a worse overall

Hosted file

Main document, vyxeos, skin rash, urbantat et al.pdf available at <https://authorea.com/users/347471/articles/473147-cpx-351-vyxeos-can-cause-severe-rash-in-acute-myeloid-leukaemia-a-case-report>

